D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 ##### Up next ![Hong Kong Banquet Market Shifts Toward Smaller-Scale Events, Runhotel.hk Data Shows](https://i0.wp.com/mma.prnasia.com/media2/2863444/image1.jpg?resize=200%2C110&ssl=1 "Hong Kong Banquet Market Shifts Toward Smaller-Scale Events, Runhotel.hk Data Shows") [](https://thailandbusinessnews.net/press-release/hong-kong-banquet-market-shifts-toward-smaller-scale-events-runhotel-hk-data-shows/) ###### [Hong Kong Banquet Market Shifts Toward Smaller-Scale Events, Runhotel.hk Data Shows](https://thailandbusinessnews.net/press-release/hong-kong-banquet-market-shifts-toward-smaller-scale-events-runhotel-hk-data-shows/) Published on 19 January 2026 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2758996/D3_BIO_DeShengJi_Logo.jpg?p=medium600 "logo") SHANGHAI, Jan. 19, 2026 /PRNewswire/ — D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 — a KRAS G12D inhibitor — enabling the start of a Phase 1 first‑in‑human clinical trial. A Phase 2 combination trial evaluating D3S‑001 (elisrasib), the Company’s next‑generation KRAS G12C inhibitor, in combination with D3S‑002, a selective oral ERK1/2 inhibitor. D3S‑003 is an orally bioavailable, allele‑specific KRAS G12D inhibitor that targets both the GDP‑bound (OFF) and GTP‑bound (ON) conformations. Preclinical data demonstrate a differentiated, best‑in‑class profile with potent anti‑tumor activity, favorable drug‑like characteristics, and a promising safety margin. With FDA clearance received, D3 Bio will advance D3S‑003 into a Phase 1 first‑in‑human study in patients with advanced solid tumors harboring KRAS G12D mutations. The newly cleared Phase 2 study will evaluate the combination of D3S‑001 and D3S‑002 in patients with KRAS G12C–mutant non‑small cell lung cancer (NSCLC) who have progressed on prior KRAS G12C‑targeted therapies. The trial, expected to begin in the first half of 2026, will investigate safety, pharmacokinetics, and early efficacy signals with the goal of establishing a rational combination strategy to address resistance and deliver more durable benefit in KRAS‑driven cancers. "We are excited to receive FDA IND clearance for D3S‑003 and to advance a Phase 2 combination clinical trial of elisrasib and D3S‑002," said George Chen, Founder, Chairman and Chief Executive Officer of D3 Bio. "With D3S‑003, we are bringing a differentiated KRAS G12D inhibitor into the clinic to address one of the most prevalent and challenging KRAS mutations. In parallel, the combination study of elisrasib and D3S‑002 pushes forward our next‑generation KRAS G12C strategy, particularly for patients who have progressed on prior KRAS G12C‑targeted therapies. Together, these milestones underline the momentum of our KRAS franchise and reinforce our commitment to delivering transformative therapies for patients with KRAS‑mutant cancers who urgently need new options." About Elisrasib (D3S-001) Elisrasib is a next‑generation KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. It covalently binds the GDP‑bound (OFF) form of KRAS G12C, effectively blocking nucleotide cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C engagement at clinically relevant exposures, and CNS penetration capability. Elisrasib is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid tumors including NSCLC, CRC, and others. Key publications: Cancer Discovery (2024) 14(9):1675–1698 Nature Medicine (2025) 31(8):2768–2777 About D3S‑002 D3S‑002 is a selective ERK1/2 inhibitor strategically designed for combination approaches, providing vertical MAPK‑pathway inhibition to enhance efficacy and overcome acquired resistance, particularly in tumors previously treated with KRAS G12C inhibitors. Key publication: Cancer Res 1 April 2023; 83 (7\_Supplement): 5501. About D3S‑003 D3S‑003 is a differentiated KRAS G12D inhibitor targeting both OFF and ON conformations to address one of the most common KRAS mutations. The program aims to broaden D3 Bio’s multi‑allele KRAS franchise and deliver new solutions for the heterogeneous and evolving landscape of KRAS‑driven cancers. About D3 Bio D3 Bio is a global biotechnology company focused on the discovery, development, and registration of novel oncology and immunology therapies with first‑ or best‑in‑class potential. Guided by deep clinical insight and biomarker‑driven strategies, the Company is advancing a pipeline of programs targeting key oncogenic drivers and immune pathways. D3 Bio owns global rights to all its programs. For more information, please visit [www.d3bio.com](https://www.d3bio.com/) [Source link ](http://www.prnasia.com/story/archive/4864992_AE64992_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/hashmicro-showcases-the-power-of-ai-driven-erp-at-singapores-leading-tech-forum/) ## HashMicro Showcases the Power of AI-Driven ERP at Singapore's Leading Tech Forum SINGAPORE, Dec. 24, 2025 /PRNewswire/ — HashMicro attended the SME AI Growth… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - December 24, 2025 [](https://thailandbusinessnews.net/press-release/soul-apps-study-exposes-the-ai-social-paradox-over-80-of-gen-z-build-real-world-ties-with-the-help-of-ai/) ![Soul App's Study Exposes the AI Social Paradox: Over 80% of Gen Z Build Real-World Ties with the Help of AI](https://i0.wp.com/r2.thailandbusinessnews.net/2025/03/image_5012648_25927390.jpg?resize=260%2C140&ssl=1 "Soul App's Study Exposes the AI Social Paradox: Over 80% of Gen Z Build Real-World Ties with the Help of AI") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Soul App's Study Exposes the AI Social Paradox: Over 80% of Gen Z Build Real-World Ties with the Help of AI SHANGHAI, March 31, 2025 /PRNewswire/ — The year 2025 marked a watershed… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - March 31, 2025 [](https://thailandbusinessnews.net/press-release/gastops-validates-chipcheck-debris-analysis-technology-for-pratt-whitney-f135-engine-lockheed-martin-f-35-lightning-ii/) ## Gastops Validates ChipCHECK® Debris Analysis Technology for Pratt & Whitney F135 Engine / Lockheed Martin F-35 Lightning II OTTAWA, ON, May 28, 2026 /PRNewswire/ — Gastops Ltd., a global leader… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - May 27, 2026 ##### Most Read - [![Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") [Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") - [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") - [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") - [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") - [![GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") [GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") - [![600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") [600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/banyan-group-announces-acquisition-of-newmark-hotels-reserves-adding-26-hotels-lodges-and-reserves-across-seven-african-countries/) ![Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries](https://i0.wp.com/mmx.prnasia.com/media/MS1990742/20260917065723EDT_image_1.jpg?resize=260%2C140&ssl=1 "Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries") ## Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries Newmark’s deep regional expertise across urban, nature and wildlife hospitality… [](https://thailandbusinessnews.net/press-release/xpeng-launches-its-next-gen-ai-flagship-suv-g9l-in-china-with-global-launch-set-for-oct-12-at-the-paris-motor-show/) ![XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show](https://i0.wp.com/mmx.prnasia.com/media/MS1990789/20260917090347EDT_image_1.jpg?resize=260%2C140&ssl=1 "XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show") ## XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show XPENG announces that the G9L will be launched in 64 global markets,… [](https://thailandbusinessnews.net/press-release/neopace-g10-pro-ai-powered-3d-replay-golf-launch-monitor-now-crowdfunding-on-kickstarter/) ![NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter](https://i0.wp.com/mmx.prnasia.com/media/MS1990613/20260917033526EDT_image_1.jpg?resize=260%2C140&ssl=1 "NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter") ## NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter Powered by TrainerIQ™, NeoPace G10 Pro combines a Triple-Cam + 24GHz Doppler… [](https://thailandbusinessnews.net/press-release/huawei-cloud-stack-all-for-ai-powering-a-new-era-of-intelligence/) ![Huawei Cloud Stack: All for AI, Powering a New Era of Intelligence](https://i0.wp.com/mmx.prnasia.com/media/MS1990748/20260917080856EDT_image_1.jpg?resize=260%2C140&ssl=1 "Huawei Cloud Stack: All for AI, Powering a New Era of Intelligence") ## Huawei Cloud Stack: All for AI, Powering a New Era of Intelligence SHANGHAI, Sept. 17, 2026 /PRNewswire/ — At HUAWEI CONNECT 2026, Huawei Cloud…